Literature DB >> 20884708

Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS.

Chiara Elena1, Francesco Passamonti, Elisa Rumi, Luca Malcovati, Luca Arcaini, Emanuela Boveri, Michele Merli, Daniela Pietra, Cristiana Pascutto, Mario Lazzarino.   

Abstract

Risk stratification in primary myelofibrosis is currently based on two international prognostic scoring systems, neither of which takes into consideration red blood cell transfusion-dependency. In 288 consecutive patients with primary myelofibrosis, red blood cell transfusion-dependency at diagnosis affects survival independently of the International Prognostic Scoring System (P < 0.001). To evaluate the dynamic impact on survival of red blood cell transfusion-dependency, we performed a Cox's regression analysis with transfusion status as time-dependent covariate in 220 regularly followed patients with primary myelofibrosis. Patients who begin red blood cell transfusions anytime (n = 80, 36%) have a significantly worse survival compared to those who continue follow up without transfusions (HR: 7.8, 95%CI: 5.1-11.9; P < 0.001). Adjusting for Dynamic International Prognostic Scoring System in a multivariate analysis, red blood cell transfusion-dependency retained an independent prognostic impact on survival. This study suggests that red blood cell transfusion-dependency should be considered to improve risk stratification of primary myelofibrosis during follow up.

Entities:  

Mesh:

Year:  2010        PMID: 20884708      PMCID: PMC3012782          DOI: 10.3324/haematol.2010.031831

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  24 in total

1.  V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis.

Authors:  Peter J Campbell; Martin Griesshammer; Konstanze Döhner; Hartmut Döhner; Rajko Kusec; Hans C Hasselbalch; Thomas Stauffer Larsen; Niels Pallisgaard; Stéphane Giraudier; Marie-Caroline Le Bousse-Kerdilès; Christophe Desterke; Bernadette Guerton; Brigitte Dupriez; Dominique Bordessoule; Pierre Fenaux; Jean-Jacques Kiladjian; Jean-François Viallard; Jean Brière; Claire N Harrison; Anthony R Green; John T Reilly
Journal:  Blood       Date:  2005-11-17       Impact factor: 22.113

2.  Anaemia characterises patients with myelofibrosis harbouring Mpl mutation.

Authors:  Paola Guglielmelli; Alessandro Pancrazzi; Gaetano Bergamaschi; Vittorio Rosti; Laura Villani; Elisabetta Antonioli; Alberto Bosi; Giovanni Barosi; Alessandro M Vannucchi
Journal:  Br J Haematol       Date:  2007-05       Impact factor: 6.998

3.  Lenalidomide therapy in myelofibrosis with myeloid metaplasia.

Authors:  Ayalew Tefferi; Jorge Cortes; Srdan Verstovsek; Ruben A Mesa; Deborah Thomas; Terra L Lasho; William J Hogan; Mark R Litzow; Jacob B Allred; Dan Jones; Catriona Byrne; Jerome B Zeldis; Rhett P Ketterling; Rebecca F McClure; Francis Giles; Hagop M Kantarjian
Journal:  Blood       Date:  2006-04-11       Impact factor: 22.113

Review 4.  Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature.

Authors:  Francisco Cervantes; Alberto Alvarez-Larrán; Juan-Carlos Hernández-Boluda; Ana Sureda; Montserrat Torrebadell; Emili Montserrat
Journal:  Br J Haematol       Date:  2004-11       Impact factor: 6.998

5.  A gain-of-function mutation of JAK2 in myeloproliferative disorders.

Authors:  Robert Kralovics; Francesco Passamonti; Andreas S Buser; Soon-Siong Teo; Ralph Tiedt; Jakob R Passweg; Andre Tichelli; Mario Cazzola; Radek C Skoda
Journal:  N Engl J Med       Date:  2005-04-28       Impact factor: 91.245

6.  What are RBC-transfusion-dependence and -independence?

Authors:  R P Gale; G Barosi; T Barbui; F Cervantes; K Dohner; B Dupriez; V Gupta; C Harrison; R Hoffman; J-J Kiladjian; R Mesa; M F Mc Mullin; F Passamonti; V Ribrag; G Roboz; G Saglio; A Vannucchi; S Verstovsek
Journal:  Leuk Res       Date:  2010-08-07       Impact factor: 3.156

Review 7.  The World Health Organization (WHO) classification of the myeloid neoplasms.

Authors:  James W Vardiman; Nancy Lee Harris; Richard D Brunning
Journal:  Blood       Date:  2002-10-01       Impact factor: 22.113

8.  Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial.

Authors:  Monia Marchetti; Giovanni Barosi; Francesca Balestri; Gianluca Viarengo; Sara Gentili; Sara Barulli; Jean-Loup Demory; Fiorella Ilariucci; Antonio Volpe; Dominique Bordessoule; Alberto Grossi; Marie Caroline Le Bousse-Kerdiles; Andrea Caenazzo; Alessandro Pecci; Antonietta Falcone; Giorgio Broccia; Cesarina Bendotti; Fredric Bauduer; Francesco Buccisano; Brigitte Dupriez
Journal:  J Clin Oncol       Date:  2004-02-01       Impact factor: 44.544

9.  Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation.

Authors:  Francesco Passamonti; Maria Luigia Randi; Elisa Rumi; Ester Pungolino; Chiara Elena; Daniela Pietra; Margherita Scapin; Luca Arcaini; Fabiana Tezza; Remigio Moratti; Cristiana Pascutto; Fabrizio Fabris; Enrica Morra; Mario Cazzola; Mario Lazzarino
Journal:  Blood       Date:  2007-04-10       Impact factor: 22.113

10.  MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.

Authors:  Yana Pikman; Benjamin H Lee; Thomas Mercher; Elizabeth McDowell; Benjamin L Ebert; Maricel Gozo; Adam Cuker; Gerlinde Wernig; Sandra Moore; Ilene Galinsky; Daniel J DeAngelo; Jennifer J Clark; Stephanie J Lee; Todd R Golub; Martha Wadleigh; D Gary Gilliland; Ross L Levine
Journal:  PLoS Med       Date:  2006-07       Impact factor: 11.069

View more
  15 in total

1.  Prognostication in primary myelofibrosis.

Authors:  Francisco Cervantes; Arturo Pereira
Journal:  Curr Hematol Malig Rep       Date:  2012-03       Impact factor: 3.952

2.  Prognostic relevance of anemia and transfusion dependency in myelodysplastic syndromes and primary myelofibrosis.

Authors:  Animesh Pardanani; Ayalew Tefferi
Journal:  Haematologica       Date:  2011-01       Impact factor: 9.941

Review 3.  Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet.

Authors:  Tiziano Barbui; Ayalew Tefferi; Alessandro M Vannucchi; Francesco Passamonti; Richard T Silver; Ronald Hoffman; Srdan Verstovsek; Ruben Mesa; Jean-Jacques Kiladjian; Rȕdiger Hehlmann; Andreas Reiter; Francisco Cervantes; Claire Harrison; Mary Frances Mc Mullin; Hans Carl Hasselbalch; Steffen Koschmieder; Monia Marchetti; Andrea Bacigalupo; Guido Finazzi; Nicolaus Kroeger; Martin Griesshammer; Gunnar Birgegard; Giovanni Barosi
Journal:  Leukemia       Date:  2018-02-27       Impact factor: 11.528

4.  Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes.

Authors:  Brady L Stein; Donna M Williams; Christine O'Keefe; Ophelia Rogers; Roxann G Ingersoll; Jerry L Spivak; Amit Verma; Jarek P Maciejewski; Michael A McDevitt; Alison R Moliterno
Journal:  Haematologica       Date:  2011-06-28       Impact factor: 9.941

5.  Disease Modification in Myelofibrosis: An Elusive Goal?

Authors:  Pankit Vachhani; Srdan Verstovsek; Prithviraj Bose
Journal:  J Clin Oncol       Date:  2022-01-27       Impact factor: 44.544

6.  Clinical characteristics and management of iron overload in 631 patients with chronic transfusion dependency: results from a multicentre, observational study.

Authors:  Joan Cid; Luis Palomera; Matías Díaz; Concha Zamora; Fernando Solano
Journal:  Blood Transfus       Date:  2013-03-14       Impact factor: 3.443

7.  Emerging therapeutic options for myelofibrosis: a Canadian perspective.

Authors:  Vikas Gupta; Lynda Foltz; Shireen Sirhan; Lambert Busque; A Robert Turner
Journal:  Am J Blood Res       Date:  2012-09-23

Review 8.  Post-ET and Post-PV Myelofibrosis: Updates on a Distinct Prognosis from Primary Myelofibrosis.

Authors:  Francesco Passamonti; Barbara Mora; Daniela Barraco; Margherita Maffioli
Journal:  Curr Hematol Malig Rep       Date:  2018-06       Impact factor: 3.952

9.  Prognostic significance of ASXL1, JAK2V617F mutations and JAK2V617F allele burden in Philadelphia-negative myeloproliferative neoplasms.

Authors:  Ipek Yonal-Hindilerden; Aynur Daglar-Aday; Basak Akadam-Teker; Ceylan Yilmaz; Meliha Nalcaci; Akif Selim Yavuz; Deniz Sargin
Journal:  J Blood Med       Date:  2015-06-01

Review 10.  Molecular Pathogenesis and Clinical Significance of Driver Mutations in Primary Myelofibrosis: A Review.

Authors:  Salem H Alshemmari; Reshmi Rajan; Ashkan Emadi
Journal:  Med Princ Pract       Date:  2016-09-21       Impact factor: 1.927

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.